# Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance), Division 3.4.2.2.4.1

Extent: E+W+S+N.I.

For classification of a substance, evidence should include any or all of the following using a weight of evidence approach:
(a) positive data from patch testing, normally obtained in more than one dermatology clinic;
(b) epidemiological studies showing allergic contact dermatitis caused by the substance. Situations in which a high proportion of those exposed exhibit characteristic symptoms are to be looked at with special concern, even if the number of cases is small;
(c) positive data from appropriate animal studies;
(d) positive data from experimental studies in man (see section 1.3.2.4.7);
(e) well documented episodes of allergic contact dermatitis, normally obtained in more than one dermatology clinic;
(f) severity of reaction may also be considered.

---
Source: https://www.legislation.gov.uk/eur/2008/1272/annex/I/division/3/division/3.4/division/3.4.2/division/3.4.2.2/division/3.4.2.2.4/division/3.4.2.2.4.1 (the official version)
Page: https://openlegislation.uk/eu-regulation-2008-1272/annex-I/division-3/division-3.4/division-3.4.2/division-3.4.2.2/division-3.4.2.2.4/division-3.4.2.2.4.1
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

